Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Radiopharmaceutical Trial

Perspective Therapeutics announced on Wednesday that it has expanded its clinical focus areas and administered the first dose of the radiopharmaceutical [212Pb]VMT-α-NET to a patient in the meningioma cohort of its ongoing Phase 1/2a study. This development marks the company’s entry into treating meningioma, a type of tumor that forms on the membranes covering the brain and spinal cord, as part of its broader research into targeted alpha-particle therapy.

The Phase 1/2a clinical trial evaluates the safety, tolerability, and preliminary efficacy of [212Pb]VMT-α-NET in patients with neuroendocrine tumors and now, specifically, those diagnosed with meningioma. The study utilizes lead-212, a radioactive isotope, to deliver targeted radiation directly to tumor cells expressing specific receptors. By expanding the trial to include this new cohort, researchers aim to gather data on how the therapeutic agent interacts with meningioma cells. The company continues to monitor the study participants for adverse events and therapeutic response as the trial progresses through its established clinical phases.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 3, 2026

Author

GOAI